INTRODUCTION
Intestinal transplantation (ITx) has shown steady improvements in graft and patient survival over the past 20 years, particularly with short-term results. Lasting improvements in long-term outcome, however, still remain a challenge. Late allograft loss due to acute rejection still remains a vexing problem, in particular because of the challenge of diagnosing acute rejection in a stable recipient long removed from an aggressive, biopsy-driven, early posttransplant monitoring protocol. Biopsy is the gold standard for the diagnosis of ITx allograft disease. Currently, we lack a reliable biomarker able to forewarn us about rejection episodes: we herein review recently published data on noninvasive allograft monitoring after ITx.
MONITORING OF THE IMMUNE SYSTEM
In kidney or liver transplant, blood tests such as creatinine level or liver function tests are suitable to determine if there is graft dysfunction: such a simple and reproducible biomarker has yet to be discovered in ITx. Currently, ITx monitoring is based on protocol biopsies. However, this is an invasive procedure which requires a skilled operator as well as an experienced histopathologist. An ideal biomarker should be noninvasive, reproducible, and with a rapid result allowing for the initiation of prompt treatment.
granzyme B and perforin after ITx by real-time polymerase chain reaction on 32 recipients (494 blood samples) during episodes of acute rejection, Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection, and posttransplant lymphoproliferative disease (PTLD). Both granzyme B and perforin are expressed in natural killer cells and cytotoxic T lymphocytes, acting as effector molecules for the induction of apoptosis in target cells. The inability to use the test in the first 28 days because of variable expression was a limiting factor. Mean levels of granzyme B and perforin in the acute rejection (granzyme B ¼ 279.7; perforin ¼ 256.7), PTLD (granzyme B ¼ 199; perforin ¼ 185.9), EBV (granzyme B ¼ 133.2; perforin ¼ 143.7), and CMV (granzyme B ¼ 151.3; perforin ¼ 144) groups were significantly higher than in the normal group (granzyme B ¼ 100.1; perforin ¼ 101.1) (all P < 0.05, except for perforin in CMV infection). Although the best accuracy was obtained for the diagnosis of acute rejection, half of the samples were eliminated because of confounding conditions, limiting the clinical applicability. Sensitivity and specificity were 80 and 79% for granzyme B and 70 and 79% for perforin, respectively, and the area under the receiver-operator characteristics curve was 0.87 for granzyme B and 0.82 for perforin. Granzyme B and perforin levels rose in only 10 of 30 episodes of rejection from eight patients at a mean of 14 days (range 3-38) prior to acute rejection. Their conclusion was that granzyme B and perforin are diagnostic markers of acute rejection even though the levels also increase in case of viral infections or PTLD. Granzyme B and perforin might act as predictive molecules but should be interpreted in a clinical, histological, and virological context. Therefore, their utility is questionable.
Fecal calprotectin
Fecal calprotectin has been widely correlated with inflammatory bowel disease activity, and has been proposed as a potential marker of ITx rejection. In an early Omaha study, fecal calprotectin levels were measured from ileostomy effluent of 68 recipients with acute rejection (n ¼ 12), viral enteritis (n ¼ 5), and nonspecific inflammation (n ¼ 16), and compared with 35 normal controls [5] . During acute rejection episodes, fecal calprotectin was significantly higher than in viral enteritis or normal controls [198 mg/kg compared with 7 and 19 mg/kg, respectively (P ¼ 0.0002)], and the cutoff level was 92 mg/kg with specificity of 77% and sensitivity of 83%, as suggested by receiver-operator characteristics. In a follow-up study by the same group, published in 2011 [6] [7] , 732 stool samples were collected from 72 recipients: because of significant interpatient variability, defining an effective general 'cutoff' level was difficult and not clinically applicable. A Miami study [8] measured fecal calprotectin on 29 recipients and a cutoff level of 100 ng/mg was considered positive. Retrospective evaluation of 122 samples revealed nonspecific results. The assay was sensitive to the identification of intestinal illnesses in general, but not useful in specifically distinguishing acute rejection from these ongoing organic intestinal problems. Finally, a report from Argentina [9] showed a good sensitivity but low specificity for the diagnosis of intestinal acute rejection. High calprotectin levels were also observed in other clinical conditions. In summary, a clear role for calprotectin as a marker of rejection has yet to be realized.
Citrulline
Serum citrulline is a nonprotein amino acid deriving from glutamine conversion within enterocytes, studied as a marker of functional enterocyte mass in short bowel syndrome. The Miami group [10] [11] [12] [13] [14] analyzed 2135 dried blood spots from 57 intestinal transplant recipients at or beyond 3 months posttransplant. Lower citrulline levels were found in presence of mild, moderate, or severe acute rejection, bacteremia or respiratory infection, in the pediatric age group, and were dependent upon the time from transplant. Using less than 13 vs. at least 13 mmoles/l as a cutoff point, levels at least 13 mmoles/l were associated with moderate or severe rejection. They confirmed their data in 2012 [15] , concluding that citrulline in ITx may serve as a noninvasive biomarker with excellent negative predictive values in the long-term follow-up of pediatric recipients. In contrast, a New York study [16] [17] [18] reported that citrulline reflects the extent of
KEY POINTS
Long-term outcome after ITx is still negatively affected by rejection.
Better graft monitoring, other than biopsy, could reduce late allograft loss.
Video endoscopy is a reliable diagnostic tool but in expert hands.
Molecules such as granzyme B and perforin, citrulline or calprotectin so far have shown questionable results in allograft surveillance.
DSAs are promising biomarkers but their management in clinical practice has still to be clarified. mucosal injury regardless of the cause, but does not seem to be a predictive marker for rejection or viral enteritis, as its values may decline only when diffuse mucosal damage has occurred. These last results were confirmed by a Madrid group [19] : they reported citrulline as a sensitive and specific biomarker of the residual functional enterocyte load, related to enteric feeding tolerance, but its prognostic value as a rejection marker was questionable. Recently, a Bologna study [20] investigated citrulline according to time from ITx, episodes of acute rejection and creatinine clearance. In total, 24 adult recipients were prospectively studied. The results were compared with those of 19 healthy controls and of 29 patients with chronic renal failure. Citrulline sensitivity and specificity in detecting acute rejection after the 45th postoperative day were 38 and 83% using citrulline threshold observed in healthy controls, and 69 and 77% using citrulline threshold adjusted for chronic renal failure degree. Their conclusion was that adjusting citrulline threshold for chronic renal failure degree almost doubled the sensitivity of citrulline as a noninvasive marker of acute rejection in ITx. Summarizing the reported studies, citrulline probably expresses an exclusionary role because its higher levels are unlikely correlated with severe acute rejection, and its major limitation is a lack of forewarning of acute rejection episodes.
Donor-specific antibodies
Donor-specific antibodies (DSAs) represent the humoral alloimmunity against donor antigens: it has been widely established in other solid organ transplants that DSAs contribute to rejection and late allograft loss. After ITx, pretransplant (preformed) DSAs are present in nearly one-third of patients and posttransplant (de novo) DSAs develop in up to 40% of recipients. Recent literature shows that preformed and/or de novo DSAs are correlated with ITx rejection and allograft loss. A Pittsburgh report in 2000 [21] addressed the impact of DSAs, reporting that a positive T-cell lymphocytotoxic crossmatch increases the frequency and severity of rejection after ITx, particularly with isolated bowel graft. In 2010, the Los Angeles group [22] showed that DSAs were associated with higher allograft loss and mortality, while a Miami study [23] correlated DSAs with more frequent and severe episodes of rejection (P ¼ 0.041). In the Miami report, DSAs were preformed (n ¼ 5, antihuman leukocyte antigen class II ¼ 3, anticlass I and II ¼ 2), de novo (n ¼ 4, 15.25 AE 4.72 days after transplantation, anti-class II ¼ 1, and anti-class I and II ¼ 3) and never (n ¼ 6). Among 63 biopsies, 30 (47.6%) had significant correlations with positive DSA (k ¼ 0.30, P < 0.001) and manifested severe rejection grade (P ¼ 0.009). In 2012, a Pittsburgh study [24] analyzed 194 primary adult recipients: complement-dependent lymphocytotoxic crossmatch (CDC-XM) was positive in 55 (28%). Human leukocyte antigen (HLA)-DSA was detectable before transplant in 49 (31%) recipients with 19 continuing to have circulating antibodies. Another 19 (18%) developed de novo DSAs. Ninety percent of patients with preformed DSAs harbored HLA class-I, whereas 74% of recipients with de novo antibodies had class-II. Most antibody-mediated rejection cases occurred in the first 3 months after transplant and patients with persistent DSAs exhibited the highest risk of antibody-mediated rejection. Preformed DSAs significantly (P < 0.05) increased the risk of acute rejection. Persistent and de novo HLA-DSA significantly (P < 0.001) increased risk of chronic rejection and associated graft loss. Inclusion of the liver was a significant predictor of better outcome (P ¼ 0.004, hazard ratio ¼ 0.347) with significant clearance of preformed antibodies (P ¼ 0.04, odds ratio ¼ 56) and lower induction of de novo DSAs (P ¼ 0.07, odds ratio ¼ 24). The Berlin group [25 && ] recently confirmed that the development of de novo DSAs following ITx is often associated with acute rejection, observing that the number of mismatched antigens and epitopes correlates with the probability of developing de novo DSAs. Different results were shown in a 2013 study by the Indianapolis group [26] : of 131 intestinal/multivisceral transplants, 27 (21%) had a positive flow cytometry crossmatch. Positive crossmatch was not associated with an increased incidence of acute rejection and graft loss (30 and 37% vs. 29 and 47%; P ¼ 0.94 and 0.35, respectively). This effect was maintained in liver-excluding transplants. The authors attributed their positive outcome to the immunosuppressive regimen based on induction by thymoglobulin and rituximab, and maintenance with tacrolimus and prednisone plus monthly doses of anti-IL-2 receptor antibody (IL-2RA) for the recipients of liver-free allografts. However, crossmatching patients was based on the less sensitive flow cytometry crossmatch assay compared with a Luminex-based assay, thus may be underestimating the impact of DSAs [23] . The virtual crossmatch, in which known recipient HLA antibodies are prospectively compared with donor HLA type, provides one mean to optimize organ allocation and minimize immunologic risk. In fact, the virtual crossmatch was recently shown [27] by the Washington DC group to allow for successful isolated ITx with acceptable shortterm outcomes in sensitized patients. A number of studies have been presented at the recent Intestinal Small Bowel Transplant Symposium held in June 2015 in Argentina. A Los Angeles report [28] confirmed that the presence of preformed or de novo DSAs leads to inferior survival outcomes following ITx. A study from the Washington DC group [29] showed that the development of de novo DSAs occurs at a rapid and high incidence after ITx. Their monitoring included weekly DSA analysis for 2 months, then monthly testing for the remaining year. If de novo DSAs appeared, then weekly monitoring was reinstituted. De novo DSAs developed in 32% recipients at a median time of 22.5 days after transplant. Liver inclusion was not associated with any difference in the development of de novo DSAs (P ¼ 0. 21) as confirmed by another study from the Palo Alto group [30] . The Indiana team also performed DSA monitoring and noted that the development of de novo DSA had a trend toward the development of chronic rejection (14 vs. 5%, P ¼ 0.21) and graft loss because of acute rejection (18 vs. 7%, P ¼ 0.14) [31 && ]. Boluda et al. [32] from Madrid showed that the presence of DSAs is linked to retransplantation, being unusual in candidates for first transplant. In summary, there is still some debate going on regarding the impact of DSAs and its use as an ITx graft monitoring tool, but a large amount of evidence shows that the presence of de novo or preformed DSAs is involved negatively in long-term graft survival. New therapeutic strategies have been developed in recent years [33] [34] [35] [36] to treat DSAs, but their description is beyond the scope of the present review.
VISUAL MONITORING OF THE GRAFT
Visual graft surveillance is the easiest one over other forms of monitoring after solid organ transplantation, because of the graft ileostomy manufactured for biopsy. Ideally, endoscopy itself through the ileostomy (or, when the stoma has been taken down, a gastroscopy or colonoscopy) should be able to monitor the graft, avoiding the more invasive biopsy procedure with the possible hazards of mucosal hematomas, bleeding, and perforations, especially in small and/or friable grafts. The Pittsburgh group examined [37] this issue, documenting that endoscopy alone would have missed 37% of cases of acute rejection in 1273 endoscopies performed in 41 children. In their initial study they used fiber-optic endoscopy, but 8 years later [38] , with the improved magnification and optical resolution, new video endoscopes have shown advantages of modern technology in detecting acute rejection after ITx.
Zoom videoendoscopy
In 2006, the Miami group [38] analyzed the videoendoscopic diagnosis of rejection, comparing it to 
CONCLUSION
In conclusion, over the last 15 years, there have been many attempts to find an alternative to biopsy for prevention and/or diagnosis of acute rejection, to improve long-term graft survival after ITx (Table 1) . Serum or fecal biomarkers (granzyme B and perforin, citrulline, calprotectin) have been analyzed by many groups, and although promising to monitor the immune system, so far they have missed their role substituting the gold standard biopsy. Recently, DSAs have shown a link to graft survival, but their clinical significance in a day-by-day laboratory monitoring is still far from being fully understood.
Zoom video endoscopy has been identified as a useful tool to support biopsy findings, but its exclusionary role as noninvasive marker of the intestinal graft probably requires technology innovations still not available on the scientific market.
